Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Artelo Biosciences Temettü

Temettü kriter kontrolleri 0/6

Artelo Biosciences şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

n/a

Ödeme oranı

Sektör ortalama getirisi	2.2%
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Hisse başına kazanç	-US$3.23
Temettü verim tahmini	n/a

Son temettü güncellemeleri

Güncelleme yok

Recent updates

Artelo jumps 21% as publication highlights pre-clinical data on drug platform

Aug 16

Artelo Biosciences (NASDAQ:ARTL) Is In A Good Position To Deliver On Growth Plans

Mar 28

Artelo Biosciences (NASDAQ:ARTL) Is In A Good Position To Deliver On Growth Plans

May 20

Is Artelo Biosciences (NASDAQ:ARTL) In A Good Position To Invest In Growth?

Feb 04

INO, VXRT, BTU and TTM among premarket gainers

Feb 02

Artelo Biosciences EPS misses by $0.04

Jan 14

Artelo Biosciences on go with cancer appetite recovery study

Nov 16

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: ARTL şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: ARTL şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

Artelo Biosciences Piyasaya Karşı Temettü Getirisi

ARTL temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (ARTL)	n/a
Pazarın Alt %25'i (US)	1.4%
Pazarın En İyi %25'i (US)	4.3%
Sektör Ortalaması (Pharmaceuticals)	2.2%
Analist tahmini (ARTL) (3 yıla kadar)	n/a

Önemli Temettü: ARTL şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, ARTL şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: ARTL şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: ARTL herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

Artelo Biosciences Temettü

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü güncellemeleri

Recent updates

Artelo Biosciences Receives FDA Clearance of its IND Application for ART26.12

Artelo Biosciences, Inc. Presents Comparative Data from Key Preclinical Studies on ART12.11 at the 34th Annual International Cannabinoid Research Society Symposium

Artelo Biosciences, Inc. Announces Data Supporting Broad Potential Utility of its FABP Inhibitor Platform

New major risk - Revenue and earnings growth

New major risk - Financial position

Artelo Biosciences, Inc. Announces Publication of Peer-Reviewed Article Highlighting FABP7 as a Promising Novel Target in Cancer Therapy

Artelo Biosciences, Inc. Announces Publication of New Peer-Reviewed Pre-Clinical Research Demonstrating ART26.12's Effectiveness in Treating and Preventing Oxaliplatin-Induced Peripheral Neuropathy

New minor risk - Shareholder dilution

New major risk - Revenue and earnings growth

Artelo Biosciences to Present Preclinical Data Showcasing Research on ART26.12 and ART12.11 in Anxiety and Depression at Neuroscience 2023

New major risk - Revenue and earnings growth

Artelo Biosciences Selects for Oral Presentation to Report Positive Research Findings on Art12.11

Artelo Biosciences, Inc., Annual General Meeting, Jun 30, 2023

Price target decreased by 16% to US$35.00

Artelo Biosciences Completes Enrollment of the Phase 1b Stage of its CAReS Clinical Trial Evaluating ART27.13 for the Treatment of Cancer-Related Anorexia and Weight Loss

High number of new directors

Artelo Biosciences, Inc. Reports Positive Pre-Clinical Results with its Novel Inhibitor to Fatty Acid Binding Protein 5

Artelo jumps 21% as publication highlights pre-clinical data on drug platform

Price target increased to US$57.50

Artelo Biosciences, Inc. Completes Enrollment of the First Three Cohorts in its CAReS Study Evaluating ART27.13

Artelo Biosciences, Inc., Annual General Meeting, Jun 24, 2022

Price target decreased to US$4.08

High number of new directors

Artelo Biosciences, Inc. Reports Positive Pre-Clinical Results for Lead Program in Cancer-Related Cachexia

Artelo Biosciences (NASDAQ:ARTL) Is In A Good Position To Deliver On Growth Plans

Artelo Biosciences Rounding A Corner With Cannabinoid-Based Therapy

Artelo Biosciences, Inc. Anticipates Accelerated Clinical Development for ART27.13

High number of new directors

Is Artelo Biosciences (NASDAQ:ARTL) In A Good Position To Invest In Growth?

High number of new and inexperienced directors

Independent Director John Beck has left the company

Relief For Cancer Patients In Artelo Bioscience Pipeline

Artelo Biosciences (NASDAQ:ARTL) Is In A Good Position To Deliver On Growth Plans

Artelo Biosciences, Inc. Appoints Tamara A. Seymour to its Board of Directors

Artelo Biosciences, Inc. Announces Positive Pre-Clinical Data Associated with Proprietary CBD Cocrystal

New 90-day high: US$1.28

Is Artelo Biosciences (NASDAQ:ARTL) In A Good Position To Invest In Growth?

Artelo Biosciences Announces Research Collaboration with Trinity College Dublin to Investigate ART27.13 for the Treatment of Cancer Cachexia

INO, VXRT, BTU and TTM among premarket gainers

Artelo Biosciences EPS misses by $0.04

New 90-day high: US$1.00

Artelo Biosciences, Inc. Appoints Gregory R. Reyes to the Company’s Board of Directors

Artelo Biosciences Announces Clinical Trial Authorization to Commence Cancer Appetite Recovery Study for the Treatment of Cancer-Related Anorexia and Weight Loss

Artelo Biosciences on go with cancer appetite recovery study

New 90-day low: US$0.65

Artelo Biosciences, Inc. has completed a Composite Units Offering in the amount of $6.6 million.

Artelo Biosciences, Inc. Receives Ethics Approval to Commence Its Cancer Appetite Recovery Phase I/II Clinical Study (CAReS) of ART27.13 for the Treatment of Cancer-Related Anorexia

New 90-day low: US$0.71

New 90-day low - US$0.94

Ödemelerde İstikrar ve Büyüme

Piyasaya Karşı Temettü Getirisi

Hissedarlara Ödenen Kazanç

Hissedarlara Nakit Ödeme

Güçlü temettü ödeyen şirketleri keşfedin